ScripLeo Pharma has posted a strong set of financials for 2024, a year which saw the Danish drugmaker nail its three ambitions of increasing top-line growth, improving profitability and advancing in innova
ScripLeo Pharma has had a busy start to 2025 on the business development front but its latest deal, a licensing pact for Shanghai Junshi Biosciences' PD-1 antibody toripalimab, has raised a few eyebrows. T
ScripA total of 37 novel drugs were approved by the European Commission in 2024, a figure only marginally higher than the 36 products that were given the go-ahead in 2023. The 2024 and 2023 figures for new
ScripCoherus BioSciences has been transitioning from a focus on biosimilars to developing and commercializing its own immuno-oncology therapies – led by anti-PD-1 agent Loqtorzi (toripalimab-tpzi) – and it